Well said amb005. I have been following discussions and think similar. If a company is performing well it will rerate.
In our case we have been doing well in the last few years, but our SP did not perform, why?. Now if there is market force/factor that is holding us down, post consolidation it will only amplify such an effect, taking us even longer to rerate. When I say market forces (I don't know who it is for now), they should be able to hold us down easily, since our MC is like 20M, consolidation is not going to change that. The example of PDN clearly shows that it is below its consolidation SP. I don't believe consolidation helps any, except if a new management takes over and they need to do a raise.
Also consider engaging Bell Potter to do these works and they take a fee of 1M, we could have reduced 50M SOI through a buyback. Or even if they only charge 500k, it is equal to 25M shares which should trigger a better rerate. Just my thoughts, if anyone has good logics for consolidation I will be keen to learn from that. I would consider any expense would be a waste of time. There are even bigger costs involved such as the executive team's time and other teams time and resources, the time we all spend unnecessarily over this, along with risks of loosing further SH value etc etc.
What our management should focus is figuring out real reasons behind our SP tragedy rather than cooking up a cosmetic solution that has no logical or supporting evidence in enhancing SP. Recently companies like AGH, CAN, LGP etc all got rerate in spite of their weaker profitability, debt etc. I think our management should not loose focus on the good job they are doing. Or are they facing greater risk of survival for any unknown reasons?
Fingers crossed, I think more SH take it up with our management and get as much information before making any decision. At present I am not convinced and not supportive of consolidation. Changing my sentiment to None from Buy. GLTAH
ECS
ecs botanics holdings ltd
Add to My Watchlist
0.00%
!
0.9¢

Chart - ECS, page-126
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $11.66M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.9¢ | $7.087K | 787.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 628718 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 7616776 | 12 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 628718 | 0.009 |
21 | 8986741 | 0.008 |
12 | 9354664 | 0.007 |
8 | 1733450 | 0.006 |
4 | 3650000 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 7609030 | 11 |
0.011 | 5131092 | 8 |
0.012 | 4271473 | 7 |
0.013 | 580000 | 2 |
0.014 | 36071 | 1 |
Last trade - 13.34pm 27/06/2025 (20 minute delay) ? |
Featured News
ECS (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online